Overview

A Study to Determine the Bioequivalence of Alogliptin and Pioglitazone When Administered as Individual Tablets and as Fixed-Dose Combination (FDC)-SYR-322-4833 BL Tablets to Healthy Russian Participants

Status:
Completed

Trial end date:
2018-07-11

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the relative bioavailability and bioequivalence of 2 strengths of the FDC tablet product SYR-322-4833 BL compared to the individual alogliptin and pioglitazone tablets in healthy Russian participants.

Phase:

Phase 1

Details

Lead Sponsor:

Takeda

Treatments:

Alogliptin
Pioglitazone